Follow the English-language Merlintrader channel on Telegram.

Four updates, four different levels of evidence

The September 9, 2026 Biotech Radar covers four announcements released on September 8. The selection focuses on what each update actually adds: randomized results, biomarkers from an early-stage study, a congress presentation of previously reported findings, and a positive topline announcement without full response percentages.

Roivant ($ROIV): mosliciguat meets PHocus endpoints, PHrontier is underway

Roivant announced positive results from PHocus, a randomized, placebo-controlled Phase 2 study enrolling 135 patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). At Week 16, mosliciguat met the primary endpoint with a 56.3% placebo-adjusted reduction in pulmonary vascular resistance (p<0.0001). Six-minute walk distance improved by 35.2 meters versus placebo, a secondary endpoint (p=0.0027).

The 52.7-meter improvement at Week 24 belongs to a prespecified exploratory analysis with nominal statistical significance. The company reported favorable tolerability and said the Phase 3 PHrontier study has already started, with enrollment underway. Roivant announcement, September 8.

Editorial perspective: controlled results combined with progress into Phase 3 make this the lead story. Efficacy and safety still need confirmation in Phase 3; the findings do not establish superiority over other drugs without a direct comparison. The SEC Form 8-K corroborates the corporate announcement but is not independent clinical validation.

Beam Therapeutics ($BEAM): BEAM-302 durability and safety update

Beam presented updated results from its open-label Phase 1/2 study of BEAM-302 in alpha-1 antitrypsin deficiency at ERS. The presentation included 29 single-dose patients and follow-up of up to 18 months. The company reported increased functional AAT and reduced mutant Z-AAT.

Mild-to-moderate infusion reactions were the most frequent related adverse events; one Part B patient experienced transient Grade 3 ALT/AST elevations without increased bilirubin. Beam says it is pursuing a potential accelerated approval pathway based on biomarkers assessed over 12 months. Dosing in its pivotal cohort began in July. Beam announcement, September 8.

Editorial perspective: the biological signal supports further development, but a small open-label study and biomarker findings do not yet establish lasting clinical benefit in the lungs and liver. The regulatory pathway described is a company objective, not an FDA approval. The sponsor announcement is the primary source consulted for these updated results. ClinicalTrials.gov, NCT06389877 corroborates the study design, rather than independently confirming the new results.

Upstream Bio ($UPB): VALIANT at ERS, with the original announcement kept in context

Upstream presented Phase 2 VALIANT results for verekitug in severe asthma. The 100 mg every-12-week regimen reduced the annualized asthma exacerbation rate by 56% versus placebo (p<0.001). The company reported generally favorable tolerability. Upstream announcement, September 8.

The chronology matters: topline results were already announced in February, as documented in the annual report filed with the SEC. September 8 is a congress update, rather than the study’s first positive announcement.

Upstream expects to initiate Phase 3 trials in severe asthma and chronic rhinosinusitis with nasal polyps in the first quarter of 2027 using 400 mg every 12 weeks. That planned regimen must not be confused with the dose associated with the 56% result. The VALIANT registry entry corroborates the study identity and design; the entry consulted does not contain posted tabular results.

Editorial perspective: the next step is the transition to Phase 3 and evaluation of the planned quarterly regimen. Timelines and success remain prospective.

Bristol Myers Squibb ($BMY): arlo-cel meets QUINTESSENTIAL endpoints

Bristol Myers Squibb announced positive topline results from the registrational Phase 2 QUINTESSENTIAL study of arlocabtagene autoleucel, or arlo-cel, a GPRC5D-directed CAR T-cell therapy in relapsed/refractory multiple myeloma. This is an open-label, single-arm study in patients previously exposed to four treatment classes, including BCMA-targeted therapies.

BMS said the primary overall response rate endpoint and key secondary endpoints were met. The announcement does not provide full response percentages; results are planned for a future medical meeting. The company described the safety profile as consistent with CAR T-cell therapies and GPRC5D-directed treatments. BMS announcement, September 8.

Editorial perspective: the full dataset, including response durability and detailed adverse events, is the next important piece of evidence. A registrational study is not an approval. The sponsor announcement is the primary source consulted for the topline outcome. The QUINTESSENTIAL registry entry provides study context.

What comes next

For ROIV, follow PHrontier execution; for BEAM, further data maturity and regulatory progress; for UPB, the planned Phase 3 starts; for BMY, the complete results. These are distinct development milestones and do not automatically rank the stocks’ investment potential.

Explore the Biotech Stocks Hub and the Merlintrader Stock Hub directory for company coverage.